Skip to content

Study · Non-randomized trial · n = 11 · 2010

3 results

A point-of-care assessment of the effects of desmopressin on impaired platelet function using multiple electrode whole-blood aggregometry in patients after cardiac surgery.

Weber CF, Dietrich W, Spannagl M, Hofstetter C, Jámbor C

Anesthesia and analgesia30 Dec 2009Cited by 34 (Europe PMC)

PMID20042444 (opens in a new tab)DOI10.1213/ane.0b013e3181c92a5c (opens in a new tab)PepBankPUB-20042444
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialActivity measurement

    After cardiac surgery, DDAVP increased median ASPItest aggregation from 15 U [8/21 U] to 49 U [30/72 U] (P < 0.001).

    In plain wordsAfter cardiac surgery, DDAVP increased platelet aggregation in the ASPItest compared with before treatment.

    Peptide
    Desmopressin
    Outcome
    IncreaseASPItest platelet aggregation
    Study

    n = 11

    Comparator
    Before intervention
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kgAs given in this study (human).

    Measurements

    ASPItest aggregation, median
    49 U
    DDAVP group, postintervention
    ASPItest aggregation, 25th/75th percentile
    30 to 72 U
    DDAVP group, postintervention
    ASPItest aggregation, median
    15 U
    DDAVP group, preintervention
    ASPItest aggregation, 25th/75th percentile
    8 to 21 U
    DDAVP group, preintervention
    P value
    < 0.001
    DDAVP group, post vs pre, ASPItest

    Source sentences

    Summary
    After the intervention, platelet function improved in the DDAVP group (49 U [30/72 U], median [25th/75th percentile] postintervention vs 15 U [8/21 U] preintervention for the ASPItest [P < 0.001]
    2 context sentences
    Summary · context
    Twenty-two patients had suspected isolated platelet dysfunction and were enrolled in the study.
    Summary · context
    Eleven patients received 0.3 microg/kg DDAVP, and 11 patients received no therapy in a nonrandomized manner.
  2. 02HumanNon-randomized trialActivity measurement

    After cardiac surgery, DDAVP increased median ADPtest aggregation from 14 U [7/28 U] to 35 U [24/54 U] (P = 0.002).

    In plain wordsAfter cardiac surgery, DDAVP increased platelet aggregation in the ADPtest compared with before treatment.

    Peptide
    Desmopressin
    Outcome
    IncreaseADPtest platelet aggregation
    Study

    n = 11

    Comparator
    Before intervention
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kgAs given in this study (human).

    Measurements

    ADPtest aggregation, median
    35 U
    DDAVP group, postintervention (median, 25th/75th percentile)
    ADPtest aggregation, 25th/75th percentile
    24 to 54 U
    DDAVP group, postintervention (median, 25th/75th percentile)
    ADPtest aggregation, median
    14 U
    DDAVP group, preintervention (median, 25th/75th percentile)
    ADPtest aggregation, 25th/75th percentile
    7 to 28 U
    DDAVP group, preintervention (median, 25th/75th percentile)
    P value
    0.002
    DDAVP group, post vs pre intervention, ADPtest

    Source sentences

    Summary
    35 U [24/54 U] vs 14 U [7/28 U] for the ADPtest [P = 0.002]
    2 context sentences
    Summary · context
    Twenty-two patients had suspected isolated platelet dysfunction and were enrolled in the study.
    Summary · context
    Eleven patients received 0.3 microg/kg DDAVP, and 11 patients received no therapy in a nonrandomized manner.
  3. 03HumanNon-randomized trialActivity measurement

    After cardiac surgery, DDAVP increased median TRAPtest aggregation from 64 U [26/88 U] to 85 U [66/115 U] (P = 0.007).

    In plain wordsAfter cardiac surgery, DDAVP increased platelet aggregation in the TRAPtest compared with before treatment.

    Peptide
    Desmopressin
    Outcome
    IncreaseTRAPtest platelet aggregation
    Study

    n = 11

    Comparator
    Before intervention
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    0.3 microg/kgAs given in this study (human).

    Measurements

    TRAPtest aggregation, median
    85 U
    DDAVP group, postintervention (median, 25th/75th percentile)
    TRAPtest aggregation, 25th/75th percentile
    66 to 115 U
    DDAVP group, postintervention (median, 25th/75th percentile)
    TRAPtest aggregation, median
    64 U
    DDAVP group, preintervention (median, 25th/75th percentile)
    TRAPtest aggregation, 25th/75th percentile
    26 to 88 U
    DDAVP group, preintervention (median, 25th/75th percentile)
    P value
    0.007
    DDAVP group, post vs pre intervention, TRAPtest

    Source sentences

    Summary
    85 U [66/115 U] vs 64 U [26/88 U] for the TRAPtest [P = 0.007]).
    2 context sentences
    Summary · context
    Twenty-two patients had suspected isolated platelet dysfunction and were enrolled in the study.
    Summary · context
    Eleven patients received 0.3 microg/kg DDAVP, and 11 patients received no therapy in a nonrandomized manner.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.